Furthermore, accumulating evidence indicates that canagliflozin can regulate WNT/β-catenin or AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling, so that to block the growth of hepatocellular carcinoma and breast cancer (18–20). This evidence concerns the gene MTOR and breast carcinoma.